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ABSTRACT
Objectives: In our institutional experience, involved-field radiation therapy (IFRT) yields 
favorable outcomes in patients with recurrent epithelial ovarian cancer (EOC). This 
retrospective study aimed to investigate the clinical benefits of IFRT in this patient population.
Methods: Among patients treated with IFRT for recurrent EOC between 2010 and 2017, 61 
patients with 90 treatments were included. IFRT encompassed all treatable lesions identified 
via imaging studies with 10–15-mm margins. Prescribed doses were ≥45 Gy (equivalent dose 
in 2 Gy/fraction).
Results: Patients were followed up for a median of 19.0 (Interquartile range, 8.6–34.9) 
months after IFRT. The 2-year in-field control, progression-free survival, and overall survival 
(OS) rates were 42.7%, 24.2%, and 78.9%, respectively. Fifty-three IFRT sessions (58.9%) 
were followed by systemic chemotherapy, and the median chemotherapy-free interval (CFI) 
was 10.5 (95% confidence interval=7.3–13.7) months. A higher carbohydrate antigen-125 
(CA-125) level correlated with a worse 2-year OS (69.2% vs. 91.0%; p=0.001) and shorter 
median CFI (4.7 vs. 11.9 months; p<0.001). Twenty-eight (31.1%) of 90 treatments yielded a 
long-term CFI >12 months. For patients with a normal CA-125 level and/or platinum-sensitive 
tumor, IFRT prolonged CFI regardless of pre-existing carcinomatosis, gross tumor volume, 
and number of treatment sites.
Conclusion: Our early experience demonstrates the safety and feasibility of IFRT as an 
effective salvage therapy and enables a “chemotherapy holiday” in selected recurrent EOC 
settings. The CA-125 value before IFRT (within normal range) and/or platinum sensitivity 
could be used as selection criteria for IFRT.
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INTRODUCTION
Currently, standard care for patients with advanced epithelial ovarian cancer (EOC) mainly 
consists of maximal cytoreductive surgery followed by platinum-based chemotherapy. 
Unfortunately, many patients will experience a disease relapse despite this regimen [1]. The 
current guidelines for salvage treatment recommend the administration of a second and 
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more chemotherapy or second cytoreductive surgery if applicable [2]. Whole-abdominal 
radiation therapy (RT) was often used as an adjuvant therapy for EOC in the 1970s and 1980s. 
However, serious toxic events led to significant concerns about this treatment modality, 
and RT was later restricted to palliative management of symptomatic metastases after the 
emergence of platinum-based chemotherapy [3].
In recent studies, volume-directed involved-field radiation therapy (IFRT) showed favorable 
locoregional control in carefully selected patients with recurrent EOC [4,5]. However, the 
patient population who would most benefit from IFRT has not been clearly defined. Since 
2010, our institution has delivered IFRT to heavily-treated patients of recurrent EOC with 
no more available chemotherapy regimens as a palliative measure, rather than salvage 
treatment. We gradually realized that IFRT yielded favorable outcomes, and multidisciplinary 
discussions led us to define a possible role for RT in a recurrent setting. Therefore, the 
present retrospective study aimed to evaluate the clinical benefits of IFRT and to identify the 
group of patients with EOC who would have the greatest benefits.
MATERIALS AND METHODS
1. Patients
Upon receiving Institutional Review Board approval (IRB Number 4-2018-1141), we retrospectively 
reviewed patients who had been histologically or clinically diagnosed with recurrent EOC at our 
center from 2010 to 2017. Informed consent was waived because of the retrospective nature 
of the study. All patients were initially treated with optimal cytoreductive surgery, followed 
by adjuvant platinum-based chemotherapy according to their pathologic stage. The inclusion 
criterion was treatment with tumor-directed IFRT either at the time of diagnosis of recurrent 
ovarian cancer or after salvage therapies, including chemotherapy and/or cytoreductive 
surgery. The exclusion criteria included a lack of initial optimal cytoreductive surgery, the 
presence of brain metastasis, or a palliative RT dose <45 Gy (equivalent dose in 2 Gy/fraction 
[EQD2]). We also excluded 31 patients from a prospective cohort enrolled in our pervious 
phase II trial [6]. After applying these exclusion criteria, 61 patients were ultimately analyzed.
2. IFRT
Patients were categorized into 3 groups according to the sequence of chemotherapy and IFRT. 
Based on Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST 1.0) 
[7], consolidative IFRT was only considered for patients presenting a metabolic complete 
response. Other sequences include salvage IFRT upon stable disease or progressive disease 
based on either Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) [8] or 
PERCIST (version 1.0) after chemotherapy. Patients who received the initial IFRT without 
chemotherapy were categorized under salvage IFRT without chemotherapy.
During each IFRT treatment, all identified lesions were treated with intensity-modulated, 
stereotactic body, or 3-dimensional conformal RT. The consistency of target volume was 
confirmed by a single gynecologic radiation oncologist (YBK). All patients underwent 
computed tomography (CT) simulations using immobilization devices depending on the 
lesion site. After CT simulation, the gross tumor volume (GTV) was contoured on the CT scan 
to include all visible lesions or the tumor bed defined following chemotherapy. The clinical 
target volume (CTV) was defined as an expansion of the GTV of up to 10–15 mm, as well as 
adjacent high-risk regions (i.e. initial tumor before chemotherapy) at the discretion of the 
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treating physician. Therefore, 2 planning target volumes (PTV) could be outlined. Initial PTV 
is CTV including GTV with a set-up margin; boost PTV is for GTV alone with a set-up margin. 
Generally, we prescribed a total 37.5 Gy in 15 fractions for initial PTV and a total of 45 Gy in 
15 fractions to boost PTV using a simultaneous integrated boost. We alternatively prescribed 
a total of 44 Gy in 20 fractions for initial PTV and a 50 Gy in 20 fractions to boost PTV 
when radiosensitive organs, such as the small bowel or duodenum, were close to PTV. For 
stereotactic body radiation therapy, a total of 30 Gy in 5 fractions or 32 Gy in 4 fractions were 
prescribed. Given the variability in the treated sites, no uniform dose constraints were placed 
for organs-at-risk. To correlate different irradiation doses with the clinical results, the EQD2 
was calculated using an assumed α/β-ratio of 10 for the tumor.
3. Follow-up
All patients were followed up until death or the time of analysis. At 3 months after planned 
RT, most patients underwent a history-taking and physical examination, standard imaging 
evaluations, and laboratory testing, including a measure of the carbohydrate antigen-125 
(CA-125) level. The responses and progression of all tumors were evaluated using the revised 
RECIST (version 1.1) [8]. Local failure was defined as tumor progression at the treated site. 
In patients in whom local failures were determined from serial assessments, each event was 
documented from the first radiographic appearance of tumor progression. After progressive 
disease following RT was confirmed, multidisciplinary team discussion based on current 
evidence and consensus settled issues regarding subsequent salvage treatments such as 
chemotherapy, supportive care, or re-irradiation. Treatment-related toxicity events were 
graded at the time of follow-up according to the Common Terminology Criteria for Adverse 
Events (version 4.03) [9].
4. Statistical analysis
The in-field control rate (IFCR) was calculated from the first date of IFRT to the date of 
subsequent failure within the IFRT field (i.e., in-field). Progression-free survival (PFS) was 
defined as the time interval from IFRT to subsequent progression (either in-field or out-
field) or death without disease, whichever occurred first. Overall survival (OS) was calculated 
in months from the first date of IFRT to the date of death, or to the last follow-up visit for 
patients who remained alive. In patients who did not receive concomitant chemotherapy, the 
chemotherapy-free interval (CFI) was calculated from the date of first IFRT to the first date of 
administration of the next chemotherapy course or the last follow-up.
The Kaplan-Meier method was used to estimate the OS, PFS, IFCR, and CFI. A Cox regression 
model was used for the multivariable analysis of factors affecting OS, PFS, IFCR, and CFI. 
In all analyses, a 2-sided p-value of <0.05 was considered to indicate statistical significance. 
All statistical analyses were performed using SPSS statistical software, ver. 23.0 (IBM, Inc., 
Armonk, NY, USA).
RESULTS
The 61 consecutive patients with 90 treatments who were included in this study had a median 
age of 54 (interquartile range [IQR], 49–61) years. The most common histology was serous 
carcinoma and was present in 49 (80.3%) patients. Patients underwent IFRT after a median 
of 2.0 (IQR, 2.0–2.4) months after the last chemotherapy course. The median CA-125 levels 
at the time of IFRT and at 3 months after IFRT were 30.0 (IQR, 10.0–87.1) and 18.1 (IQR, 5.6–
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123.3) U/mL, respectively. More than half of patients received 2 or 3 courses of chemotherapy 
before IFRT. Details of the patients' characteristics are presented in Table 1.
One-third of the treatment cases (30 cases, 33.3%) met the category of consolidation IFRT 
after a metabolic complete response to chemotherapy, 27 cases (30.0%) involved salvage IFRT 
despite a variable or poor response to chemotherapy, and 33 cases (36.7%) were categorized into 
initial salvage IFRT without chemotherapy. Ninety treatments were administered to 61 patients 
at a median prescription dose of EQD2 50.8 (IQR, 48.8–55.9) Gy and a median dose per fraction 
of 2.2 (IQR, 2.0–2.5) Gy. Individual doses were based on the target volume. The prescribed 
dose significantly differed among sequences of IFRT (p<0.003). For 30 cases with consolidative 
IFRT, a median prescription dose was EQD2 47.5 (IQR, 44.0–54.0) Gy and a median dose per 
fraction of 2.1 (IQR, 2.0–3.0) Gy. A median EQD2 54 (IQR, 50.0–56.2) Gy was prescribed 
in the salvage IFRT following chemotherapy, and a median EQD2 50.0 (IQR, 45–54 Gy) was 
prescribed in the salvage IFRT without chemotherapy. Most treatments were administered 
to extra-abdominal sites with regional area (36 cases, 40.0%) following treatments to nodal 
areas such as pelvic, paraaortic, or inguinal lymph nodes (25 cases, 27.8%). A total of 172 sites 
were treated, of which the paraaortic and mediastinal lymph nodes were the most frequent. 
Further treatment details are presented in Table 2 and Supplementary Table 1.
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Table 1. Patient and treatment characteristics
Characteristics Per patient (n=61) Per treatment (n=90)
Age (yr) 54.0 (48.5–61.0) 53.5 (48.0–60.0)
ECOG PS
ECOG 0–1 53 (86.9) 77 (85.4)
ECOG 2–3 8 (13.1) 13 (14.4)
Pathology
Serous 49 (80.3) 75 (83.3)
Endometrioid 5 (8.2) 7 (7.8)
Clear cell 4 (6.6) 5 (5.6)
Other 3 (4.9) 3 (3.3)
BRCA
Negative 17 (27.9) 24 (26.7)
BRCA1 10 (16.4) 15 (16.7)
BRCA2 4 (6.6) 5 (6.7)
BRCA1/2 2 (3.3) 6 (5.6)
Unknown 28 (45.9) 40 (44.4)
Platinum sensitivity
Platinum sensitive (mo)* 10.5 (5.0–23.4) 11.3 (5.7–22.3)
Sensitive (≥6 mo) 26 (42.6) 37 (41.4)
Resistant (<6 mo) 35 (57.4) 53 (58.9)
Carcinomatosis before IFRT
Absent 32 (52.5) 41 (45.6)
Present 29 (47.5) 49 (54.4)
CA-125 before IFRT 35.6 (9.9–86.4) 30.0 (10.0–87.1)
CA-125 after IFRT 17.6 (7.8–114.0) 18.1 (5.6–123.3)
Courses of chemotherapy before IFRT
1 12 (19.7) 12 (13.3)
2 29 (47.5) 43 (47.8)
3 14 (23.0) 21 (23.3)
4–5 6 (9.8) 14 (15.5)
CFI before IFRT (mo)† 2.0 (1.4–5.3) 2.3 (1.5–10.2)
Values are presented as number (%) or median (IQR).
CA-125, cancer antigen-125; CFI, chemotherapy-free interval; ECOG, Eastern Cooperative Oncology Group; IFRT, 
involved-field radiation therapy; IQR, interquartile range; PS, performance status.
*Platinum sensitive duration refers to the time from the end of the first-line taxane based chemotherapy to the 
day of first recurrence; †CFI before IFRT refers to the time from the last chemotherapy to the radiation therapy.
During a median follow-up of 19.0 (IQR, 8.6–34.9) months, the 1- and 2-year IFCRs and median 
in-field control duration were 66.9%, 42.7%, and 18.4 months, respectively. Forty-eight cases 
(53.3%) experienced in-field failures at a median interval of 9.6 (IQR, 5.1–18.1) months after 
IFRT. Early in-field failures within 12 months (n=44) have shown distinct pre-treatment features 
compared to that of others. The median CA-125 level at the time of IFRT of early failures was 
52.8 (IQR, 15.6–113.1) compared to 19.5 (IQR, 7.8–65.4) U/mL of other cases (p=0.012). There 
are certain circumstances for early recurrences; treatment-resistant tumors such as 3 or more 
cycles of pre-IFRT chemotherapy (n=4), previous IFRT (n=2), platinum-resistant tumors (n=9), 
high CA-125 level at the time of IFRT (n=26), or prescription dose less than EQD2 50 Gy (n=3). 
The median follow-up period for patients with disease control status after IFRT was 14.8 (IQR, 
7.2–32.8) months. In the multivariate analysis, a higher prescribed dose (EQD2 ≥50 Gy) was 
associated with better in-field control (p=0.002) (Supplementary Table 2).
Following IFRT, 53 cases (58.9%) received salvage chemotherapy after progression at a 
median CFI of 10.5 (95% confidence interval [CI]=7.3–13.7) months (Fig. 1). Further analysis 
identified platinum sensitivity (p=0.020) and the CA-125 level at the time of IFRT (p<0.001) 
as significant prognostic factors for the re-administration of salvage chemotherapy after IFRT 
(Supplementary Fig. 1). There was no statistical difference in CFI according to GTV volume, 
treatment sequence, pre-treatment carcinomatosis, and CFI before IFRT (Table 3). As shown 
in Fig. 1, the 2-year PFS and OS rates of the entire cohort were 24.2% and 78.9%, respectively.
A subgroup analysis stratified by the CA-125 level (35 U/mL) at the time of IFRT and platinum 
sensitivity revealed disparities in CFI (Fig. 2). Patients with a normal CA-125 level at the time 
of IFRT and platinum-sensitive tumors (n=25) had the longest median CFI of 12.6 (IQR, 
7.0–25.7) month, with 1- and 2-year CFI rates of 86.9% and 66.8%, respectively. They did 
not reach median OS with 2-year OS rate of 82.9%. By contrast, patients with an elevated 
CA-125 level and platinum-resistant tumors (n=31) had the shortest CFI, with a median 
duration of 4.7 (IQR, 3.0–7.1) months. Median OS in this group was reached at 23.3 months 
and 2-year OS was 47.2%. Patients with a normal CA-125 level and platinum-resistant tumors 
(n=22) exhibited a relatively longer median CFI after IFRT when compared to those with an 
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Table 2. Treatment details of IFRT
Treatment details Per patient (n=61) Per treatment (n=90)
Treatment sequence
Consolidation after chemotherapy 23 (37.7) 30 (33.3)
Salvage after chemotherapy 24 (39.3) 27 (30.0)
Salvage without chemotherapy 14 (23.0) 33 (36.7)
Treatment sites
Nodal area (pelvic, paraaortic, inguinal) 15 (24.6) 25 (27.8)
Extra-nodal pelvic area 10 (26.4) 12 (13.3)
Multiple regional area (nodal with extra-nodal area) 7 (11.5) 10 (11.1)
Extra-abdominal sites with regional area 24 (39.3) 36 (40.0)
Extra-abdominal sites without regional area 5 (8.2) 7 (7.8)
GTV volume (mL) 12.8 (4.4–31.1) 12.7 (4.3–29.6)
Total dose (Gy) 50.4 (48.4–55.0) 50.1 (45.0–55.0)
Total dose (EQD2) (Gy) 52.1 (49.5–55.9) 50.8 (48.8–55.9)
Fractional dose (Gy) 2.0 (2.0–2.4) 2.2 (2.0–2.5)
IFRT modality
3D CRT 33 (54.1) 34 (37.8)
IMRT/SBRT 28 (45.9) 56 (62.2)
Values are presented as number (%) or median (IQR).
3D-CRT, 3 dimensional-conformal radiation therapy; EQD2, equivalent dose in 2 Gy per fraction; GTV, gross tumor 
volume; IFRT, involved-field radiation therapy; IMRT, intensity modulated radiation therapy; IQR, interquartile 
range; LN, lymph node; SBRT, stereotactic body radiation therapy
abnormal CA-125 level and platinum-sensitive tumors (n=12) (median CFI, 17 [IQR, 5.4–26.1] 
vs. 9.8 [IQR, 2.6–10.8] months; 2-year CFI rate, 47.9% vs. 20.8%; p<0.001).
We further discriminated long-term chemotherapy free group, long-term group (28 cases, 
31.1%), from the short-term chemotherapy free group, short-term group (62 cases, 68.9%), 
based on a CFI of >12 months after IFRT (Supplementary Table 3). Each group had a median 
CFI of 27.4 (IQR, 19.4–36.6) and 5.0 (IQR, 2.9–7.4) months, respectively. In 13 of the 28 
cases (46.4%) involving the long-term group, IFRT was limited to a single site; otherwise, 
multiple sites were treated, including 2 sites in 7 cases, 3 sites in 5 cases, and 4 sites in 3 cases. 
Notably, the proportion of platinum-sensitive tumors was much higher in the long-term 
group. Although the rate of pre-existing peritoneal carcinomatosis did not differ between the 
groups, significant differences in the CA-125 level before RT and the change in CA-125 (ratio 
of CA-125 from before to after IFRT) were observed between the long-term and short-term 
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Fig. 1. CFR, PFS, and OS of the entire cohort. 
CFR, chemotherapy-free rate; OS, overall survival; PFS, progression-free survival.
Table 3. Prognostic factors of interval of chemotherapy administration after IFRT
Prognostic factors 2yr CFI 
(%)
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Age at IFRT (yr) 33.9 1.04 0.61–1.78 0.889 - - -
(≥median vs. <median) 37.1
Pathology 31.8 1.43 0.67–3.06 0.352 - - -
(serous vs. others) 46.7
Platinum sensitivity 24.5 2.71 1.46–5.02 0.002 2.13 1.13–4.01 0.020
(resistant vs. sensitive) 52.3
CA-125 before IFRT (U/mL) 12.4 4.59 2.54–8.28 <0.001 4.04 2.21–7.38 <0.001
(≥35 vs. <35) 58.3
Total dose (EQD2) (Gy) 20.0 1.59 0.89–2.85 0.115 - - -
(<50 vs. ≥50) 41.4
GTV (mL) 24.1 1.57 0.91–2.71 0.108 - - -
(≥median vs.<median) 45.6
Treatment sequence 35.1 1.10 0.60–2.00 0.763 - - -
(salvage vs. consolidation) 37.7
Carcinomatosis before IFRT 26.4 1.44 0.83–2.51 0.192 - - -
(present vs. absent) 47.9
CFI before IFRT (mo) 39.6 1.02 0.60–1.76 0.929 - - -
(<median vs. ≥median) 31.5
CFI before IFRT refers to the time from the last chemotherapy to the radiation therapy.
CA-125, cancer antigen-125; CFI, chemotherapy-free interval; CI, confidence interval; EQD2, equivalent dose in 2.0 Gy per day fractions; GTV, gross tumor volume; 
HR, hazard ratio; IFRT, involved-field radiation therapy.
groups. These groups also differed significantly in terms of OS, with 2-year rates of 92.7% 
and 67.8%, respectively (p=0.003, Fig. 3).
In an analysis of the subgroup of cases with an elevated CA-125 value (≥35 U/mL) before IFRT, 
the long-term group (5 cases) and short-term group (38 cases) differed significantly in terms 
of the change in CA-125 levels (0.34 vs. 1.69, p<0.001). By contrast, in the subgroup of cases 
with a normal CA-125 value before IFRT, the change in CA-125 levels did not differ statistically 
between 2 groups (0.98 vs. 3.15, p=0.176).
1. Toxicity
IFRT was well-tolerated and usually did not induce major acute treatment-related toxicities. 
The acute and late toxicities reported in this study are shown in Supplementary Table 4. No 
grade 3 toxicity events were recorded during or shortly after IFRT. Most patients (39 patients, 
43.3%) experienced grade 1 or 2 nausea. Furthermore, no grade 3 or more late toxicity events 
were reported.
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Fig. 2. Chemotherapy-free rates prior to involved-field radiation therapy and platinum sensitivity, stratified by the 
CA-125 level. 
CA-125, carbohydrate antigen-125.
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Fig. 3. OS stratified by the chemotherapy free after involved-field radiation therapy. 
OS, overall survival; CFI, chemotherapy-free interval.
DISCUSSION
In this single-institutional cohort study, we retrospectively reviewed 90 cases of IFRT 
administered to 61 patients with recurrent EOC. Notably, patients in a third of these cases 
remained free from additional chemotherapy for more than 12 months after IFRT. Furthermore, 
we identified both platinum sensitivity and the CA-125 level as independent factors associated 
with chemotherapy re-administration. Specifically, patients with both platinum-sensitive 
tumors and a CA-125 level within the normal range before IFRT had the longest CFI after IFRT. 
The long-term chemotherapy free group that achieved a CFI of >12 months had the following 
distinct tumor and treatment characteristics: platinum sensitivity and a higher EQD2 dose (≥50 
Gy) delivered with curative intent, irrespective of the GTV. A moderate decrease in the CA-125 
level after IFRT was also found to correlate with the long-term CFI outcomes of patients with 
initially abnormal CA-125 levels. Our experience suggests that the appropriate determination of 
patients with recurrent EOC who would most benefit from IFRT could yield the achievement of 
long-term control without requiring further chemotherapy.
Several previous studies have explored the ability of IFRT to provide favorable local control 
outcomes in patients with recurrent ovarian cancer [4,10-16]. The largest single-center 
retrospective experience of IFRT, conducted by Brown et al. [4], reported that 35% of 
patients had no evidence of disease at 28 months after IFRT, as well as a 5-year local control 
rate of 71%. Brown and colleagues [4] also demonstrated a notably longer treatment break 
immediately after IFRT than immediately prior to IFRT, although these chemotherapy breaks 
decreased gradually with each additional chemotherapy course.
Brown and colleagues noted that in their cohort of 102 patients, most treatment sites were 
located in the pelvis (54%) and abdomen (44%) [4]. Recently, Lazzari et al. [10] studied 109 
cases of stereotactic body radiation therapy in 82 patients with oligometastatic ovarian cancer 
who received a total dose of 24 Gy in 3 fractions to the following treatment sites: abdomen/
pelvis (79%), thorax (17%), and head and neck (4%). The authors demonstrated that 47.7% 
(52 cases) remained chemotherapy-free for a median duration of 7.3 months. These findings 
are consistent with our observation that IFRT is associated with good long-term control in 
selected patients; specifically, we observed a median CFI of 10.5 months for the entire cohort 
vs. 24.7 months for the long-term group. However, the distribution of treatment sites in 
our cohort was unique, as the cases were roughly equally divided among the pelvis (31.9%), 
abdomen (36.0%), and other sites (32.1%), including the mediastinum, supraclavicular and 
axillary lymph nodes. We also observed the achievements of disease control status after IFRT 
even after including up to 5 treatment sites.
Measurement of the serum CA-125 level is a widely available means of determining the tumor 
burden and evaluating treatment responses in patients with EOC [17]. Several studies have 
already confirmed the CA-125 level as a predictor of the tumor burden after cytoreductive 
surgery. For example, Suidan et al. [18] defined 3 clinical and 8 radiologic criteria for 
the prediction of suboptimal surgery and reported that a CA-125 level >600 U/mL was 
significantly associated with residual disease after debulking surgery. Consistent with those 
earlier findings, we identified an elevated CA-125 level as a significant independent factor 
affecting treatment outcomes, suggesting that a normalized CA-125 level before IFRT reflects 
a microscopic residual tumor burden after chemotherapy. In this context, gross tumor-
directed IFRT could have a considerable effect on treatment outcomes. However, we observed 
5 cases with achievements of long-term chemotherapy delay among patients with higher CA-
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125 levels. Further analysis revealed that those cases exhibited significant changes in CA-125 
levels from before to after IFRT. Further investigation is needed to determine the mechanisms 
underlying the observed discrepancies in the changes in CA-125 levels after IFRT.
We also demonstrated that platinum sensitivity is an important factor affecting CFI after 
IFRT, consistent with the findings of previous series [4,19]. Although patients with platinum-
resistant tumors had poor outcomes after IFRT, the 22 patients in this category who had 
normal CA-125 levels before IFRT might still have benefitted from IFRT in terms of a longer 
CFI. Other clinicopathological factors, such as age, pathology, peritoneal carcinomatosis, 
and extent of the GTV, did not appear to affect the applications of IFRT.
Our results provide insights into potential clinical situations wherein IFRT might be useful 
for the treatment of recurrent EOC, including consolidation in cases with favorable responses 
after salvage chemotherapy, salvage for cases involving variable post-chemotherapy responses 
of recurrent lesions, and lesions that recurred outside the extent of debulking surgery or in 
patients who refused further chemotherapy. The stratification of such cases by the pre-IFRT CA-
125 level and platinum sensitivity status could help to determine the potential benefits of IFRT.
Although more than half of all patients experienced controlled local disease with a median 
in-field control duration of 18.4 months, approximately 50% of cases in the current 
study experienced in-field local failure. Due to the lack of an appropriate radiation dose 
recommendation, we initially started an IFRT for a few patients with a relatively low but safe 
radiation dose (EQD2 45 Gy). This high local failure rate can be explained by the inclusion 
of patients in this early era. After early experiences, we elevated the radiation dose more 
than 50 Gy, and even adopted SBRT. We also observed comparable local control with this 
dose regimen; this remains below the dose that Brown et al. [4] recommended, as shown in 
a previous prospective phase II trial [6]. Further studies are required to identify the optimal 
dose for better local control.
In addition, we observed no correlation between in-field local control and the tumor 
location or size and found no difference in local control with respect to nodal vs. extranodal 
involvement (2-year IFCR, 41.0% vs. 45.9%, p=0.896). By contrast, Fujiwara et al. [13] 
reported better response rates for nodal vs. extranodal sites, and Lee et al. [19] demonstrated 
an association of smaller tumors with better in-field local control in another series. In our 
study, we instead observed a strong correlation between a higher prescribed EQD2 and in-
field local control. A retrospective analysis by Choi et al. [16] also discovered that RT dose 
more than 50 Gy was correlated with better local control. Furthermore, Yahara et al. [15] 
also found achievement of better local control after a median dose of 60 Gy without severe 
toxicity. Currently available techniques, such as intensity-modulated and stereotactic body 
RT, enable the administration of highly ablative radiation doses. In this context, Lazzari et al. 
[10] reported the efficacy and the safety of stereotactic body RT for oligometastatic ovarian 
cancer. They reported excellent 2-year local control of 68% with 60% of complete response 
in 82 patients (156 lesions) with a median dose of 24 Gy in 3 fractions. However, the fact that 
most failures (90.0%) were outside of radiation field with inferior 3-year PFS (8%) should be 
interpreted with caution. The high frequency of out-field recurrences might be associated 
with uncontrolled microscopic disease mainly due to platinum resistance. Firstly, we could 
infer that it is very important to select the patient who could have clinical benefit from RT. 
In other words, platinum-sensitive tumors are more appropriate candidates for IFRT than 
platinum-resistant tumors to avoid short-term early out-field disease progression. Secondly, 
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the new surrogate endpoint such as progression free survival after next line of treatment (PFS2) 
[20] might be introduced for identifying the potential role of IFRT in this recurrent setting.
Our study had several limitations of note. First, this was a retrospective analysis, and the 
results should be reviewed cautiously. Second, this was a single-center study and is therefore 
subject to bias associated with such studies. Despite these limitations, however, our work 
provides another analysis of a large pool of retrospective data regarding the effects of IFRT for 
recurrent EOC.
We demonstrated that IFRT can yield excellent treatment outcomes in patients with 
recurrent ovarian cancer, irrespective of the administration of cytotoxic chemotherapy. 
Additionally, patients with a normal CA-125 level and/or platinum-sensitive tumors may be 
good candidates for IFRT with an adequate radiation dose, irrespective of the peritoneal 
carcinomatosis status, number of sites, and GTV. Further studies are warranted to elucidate 
the role of IFRT in the course of treatment for recurrent ovarian cancer.
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